SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is dominating discussion, with traders focused on whether results and forward guidance can exceed already elevated expectations. Bulls point to AI demand and growth, while skeptics warn that the premium valuation and broader tech weakness could leave the stock vulnerable even after a beat.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA accelerated approval of VOCERYQ for recurrent respiratory papillomatosis has renewed focus on competition for Precigens PAPZIMEOS, which treats the same disease. Traders debate whether VOCERYQs treatment approach will challenge PAPZIMEOS or whether Precigens first-mover advantage, full approval, and established commercial launch will help it retain an edge.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians better-than-expected third-quarter results and raised full-year outlook drove a sharp rally, with traders highlighting stronger bookings, cost control and improving yields. The subsequent pullback is being debated as profit-taking and broad market weakness, while fuel costs, debt and lingering concerns about demand remain bearish counterpoints.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention ahead of its Q3 earnings report, with investors focused on Auvelitys launch for Alzheimers agitation, prescription growth, and the path to profitability. The steep share-price decline and managements limited commentary have intensified debate: bears worry that uptake is weaker than expected and costs remain high, while bulls argue that samples and long-term-care channels may be obscuring demand and expect the report to clarify the trend.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

A Defense Department grant to expand U.S. production of Amprius batteries for drones is the main catalyst, with traders viewing it as strategic validation and potential support for future demand. The initial rally faded, prompting debate over whether the long-term capacity boost outweighs uncertainty about customer orders, revenue impact, and the facilitys later ramp-up.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high, alongside heavy call-option activity, has fueled speculation about a possible buyout and short covering ahead of Q3 results. The acquisition talk is unconfirmed; others point to BRIUMVIs sales growth and upcoming subcutaneous data as the underlying story, while cautioning that earnings and clinical milestonesnot rumorswill matter.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rockets quarterly results are drawing attention, with bulls praising profitability and market-share gains despite a difficult housing market. The reaction is tempered by concerns about weaker near-term guidance, soft mortgage demand, and elevated Treasury yields and mortgage rates; traders debate whether lower rates could revive the business.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak forward outlook following its quarterly report, with PC demand pressure and supply constraints weighing on expectations, drove a steep selloff. Traders are divided between dip buyers calling the drop an overreaction and bears who see the guidance and execution concerns as signs of deeper problems, amid broader weakness in chip and AI stocks.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

Healthcares strong rally and relative outperformance are drawing attention, with traders describing a rotation from technology into the sector and pointing to XLVs breakout and fresh highs. Some see healthcare as a defensive haven, while others caution that the rally could lose momentum.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians Q3 results beat expectations and its delivery outlook improved, with the R2 ramp drawing attention; a Jefferies upgrade added to the bullish case. Traders see improving execution and demand, while skeptics question the muted share-price reaction and ongoing cash burn and automotive losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsPR...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN FRANCISCO, Oct. 23, 2026 SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Equity

Nektar on Thursday announced data from two trials of its drug rezpegaldesleukin in alopecia and eczema. 


New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis...

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV...

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026PR NewswireSAN...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN FRANCISCO, Sept. 25, 2026 SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, Aug. 28, 2026 SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Bearish Sentiment

<ul class="summary-bullets"><li>Between week 36 and week 52 of the mid-stage REZOLVE-AA alopecia study, 29% of patients on the lower dose and 31% on the higher dose newly reached a level of hair coverage that leaves 20% or less of the scalp bare.</li><li>In the companion REZOLVE-AD study in moderate to severe atopic dermatitis, patients who switched to monthly or every-three-month injections largely held their gains in rash clearance and itch through week 52.</li><li>William Blair analyst Andy Hsieh kept an Outperform rating, saying the update adds to evidence that rezpeg has a material durability advantage over current standard treatments.</li></ul><p>Shares of Nektar Therapeutics (<a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a>) fell sharply by 21% on Thursday even as the company reported that its experimental skin drug, rezpegaldesleukin, kept working after treatment stopped, though the new response rates were modest and drawn from small patient groups.</p><p>The stock is now on track for its worst day since February 2023, if the losses hold. Analysts at William Blair and Jefferies, however, kept their bullish ratings on the stock.</p><h2 class="st-heading-2"><a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a>'s Alopecia Data&nbsp;</h2><p>Rezpegaldesleukin, or rezpeg, is designed to stimulate regulatory T cells, a part of the immune system that can calm attacks on the body’s own tissue. In severe alopecia areata, that attack strips hair from the scalp.</p><p>Between week 36 and week 52 of the mid-stage REZOLVE-AA alopecia study, 29% of patients on the lower dose and 31% on the higher dose newly reached a level of hair coverage that leaves 20% or less of the scalp bare. Those groups numbered only 14 and 13 patients. The claim that benefit held after dosing stopped rests on eight patients. None of the patients given a placebo newly reached the study’s main measure of success over that same stretch.</p><p>Among patients who had already responded after a year of treatment, 75% still met the threshold four months after stopping the drug, and 63% still did at six months, the company said.</p><p>Deeper regrowth, covering at least 90% of the scalp, rose from 7% at week 52 to 19% six months off treatment. Investigator David Rosmarin said existing systemic therapies have not shown this degree of lasting benefit and further regrowth after treatment ends. Safety through 52 weeks was described as favorable and consistent with earlier reports.</p><h2 class="st-heading-2">Eczema Trial Also Shows Improvement</h2><p>In the companion REZOLVE-AD study in moderate to severe atopic dermatitis, patients who switched to monthly or every-three-month injections largely held their gains in rash clearance and itch through week 52. The share reaching complete clearance rose several-fold on continued dosing.</p><p>Nektar has started a third late-stage eczema study in patients who already tried a biologic or a JAK inhibitor, and plans to open a roughly 850-patient late-stage alopecia trial, ZENITH-AA, in early 2027.</p><h2 class="st-heading-2"><a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> Analysts Disagree</h2><p>William Blair analyst Andy Hsieh kept an 'Outperform' rating on the stock, saying the update adds to evidence that rezpeg has a material durability advantage over current standard treatments. The firm pointed to an atopic dermatitis data update expected in the first quarter of 2027 as the next major catalyst.</p><p>Jefferies analyst Roger Song, meanwhile, called Thursday's selloff "unwarranted." The firm continues to see alopecia areata as "an underappreciated and untapped disease space" for rezpegaldesleukin. Jefferies has a $150 price target on the stock and a ‘Buy’ rating.</p><h2 class="st-heading-2">LLY Overhang On <a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> Stock</h2><p>A separate legal fight with Eli Lilly is still unresolved. The companies partnered in 2017 to develop rezpeg, but Lilly later bought a rival eczema drug and ended the deal. Nektar sued for about $1 billion; a jury in September awarded only $90 million plus interest, and Lilly plans to challenge the verdict, so the money is not yet in hand.</p><h2 class="st-heading-2">How Did <a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed ‘high.’</p><p>A Stocktwits user said the stock has been stuck for years, the recent win against Eli Lilly wasn't really a win, and the company has nothing new coming that would change that.</p><p><stembedurl>https://stocktwits.com/nab72/message/665553318</stembedurl></p><p>Another user, however, opined that Lilly might try to buy out Nektar.</p><p><stembedurl>https://stocktwits.com/george4it/message/665543981</stembedurl></p><p><a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> stock has gained 12% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-could-face-an-faa-panel-on-software-glitch-this-week-as-max-10-certification-delay-holds-report/cZD0hEqRB0Q">Boeing Could Face An FAA Panel On Software Glitch This Week As Max 10 Certification Delay Holds: Report</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Between week 36 and week 52 of the mid-stage REZOLVE-AA alopecia study, 29% of patients on the lower dose and 31% on the higher dose newly reached a level of hair coverage that leaves 20% or less of the scalp bare.In the companion REZOLVE-AD study in mode

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$38.87
Prev Close	$39.18
Open	$39.00
Dividend Yield	0.00%
50-Day Moving Average	$55.69
Beta	1.73
Avg. Volume	1.36M
PE Ratio	-5.80

52-Week High	$109.00
52-Week Low	$33.40
Market Capitalization	$1.33B
EPS (Annual)	-$9.73
Price to Book	1.47
Revenue Per Employee	$876,698.41

Feed

News

Sentiment

Earnings

Fundamentals

Info

NKTR Fundamentals